Multiple Myeloma

>

Latest News

The 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.
JNJ-79635322 Shows Safety/Favorable Responses in R/R Multiple Myeloma

June 6th 2025

The 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.

MagnetisMM-6 Data Suggest Safety, Manageability of Elranatamab Combo in NDMM
MagnetisMM-6 Data Suggest Safety, Manageability of Elranatamab Combo in NDMM

June 3rd 2025

Daratumumab Plus KRd May Be a New SOC Option in NDMM
Daratumumab Plus KRd May Be a New SOC Option in NDMM

June 3rd 2025

Results from the PERSEUS trial support daratumumab plus bortezomib, lenalidomide, and dexamethasone as a standard of care in transplant-eligible NDMM.
Subcutaneous Daratumumab Combo Sustains MRD-Negative Status in NDMM

June 3rd 2025

Subgroup data from the CEPHEUS trial reinforce daratumumab plus bortezomib, lenalidomide, and dexamethasone as a standard of care in this population.
Daratumumab Combo Improves Outcomes in Transplant-Ineligible NDMM Subgroups

June 2nd 2025

Video Series
Video Interviews
Podcasts
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.
Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
Krina Patel, MD, MSc, discusses research and initiatives that may help to mitigate disparities in patients with multiple myeloma including factors such as gender, race, and ethnicity.
Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.

More News